- Pegaptanib sodium (Macugen)
- Verteporfin (Visudyne PDT)
- Ranibizumab (Lucentis)
- None of the above
- All of the above
Correct Answer: Verteporfin (Visudyne PDT)
Although typically reimbursed for the described diagnosis, verteporfin is FDA approved in fact only for the treatment of subfoveal CNV predominantly classic due to neovascular AMD.